Associate Professor Giuseppe Verdile
- Vascular and metabolic disorders
- Neurological disorders
With a dramatic increase in people with age-related neurodegeneration and dementia expected over the next few decades, and no effective disease-modifying treatments available, Giuseppe’s research is focused on understanding risk factors that promote onset and finding new and improved pharmacological interventions to slow the progression of their leading cause – Alzheimer’s Disease (AD).
Giuseppe’s team’s made significant contributions to understanding how an enzyme called gamma secretase and its components contribute to neurodegenerative processes that occur in the brain with AD. There’s hope the findings will pave the way for the development of new drugs to treat AD that specifically target this enzyme.
Risk factors such as Type 2 diabetes (T2D) are known to promote AD pathology and disease onset. The teams research has identified that T2D is associated with early changes in cognition and AD biomarkers and has shown that proteins usually associated with AD (amyloid beta protein) may also promote T2D, exacerbating the neurodegenerative process. Understanding this process may lead to avenues to slow down disease progression.
Research interests – selectively targeting the enzyme responsible for amyloid-ß (Aß) production; investigating underlying mechanisms linking Type 2 diabetes and Alzheimer’s disease; understanding the link between stress and Alzheimer’s disease: insight into the effects of glucocorticoid related gene variants on microglial activity.